院前急性行为障碍的管理:院前环境中严重激越的处理——一项系统性文献综述
该系统性综述检索了截至2025年2月的PubMed、Cochrane、Embase、Web of Knowledge、Google Scholar和MEDLINE,纳入42项研究,评估院前急性行为障碍(ABD)的管理证据。结果显示,氯胺酮在研究中显示最有效的镇静作用(79-98%的患者达到研究定义的充分镇静),但剂量和给药方法差异很大;咪达唑仑与其他药物相比副作用更多;氟哌利多未显示更高死亡率,且对QT间期无影响。作者结论认为氯胺酮是院前ABD研究最多的药物,可能是最有效的镇静方法,剂量为5 mg/kg肌内注射;咪达唑仑呼吸相关副作用风险较高。证据质量有限,需进一步研究确定最佳给药方式和剂量。
要点
- 氯胺酮在院前ABD镇静中显示最有效,79-98%的患者达到研究定义的充分镇静,但各研究剂量和给药方法差异显著。
- 作者认为氯胺酮可能是院前ABD最有效的镇静方法,剂量为5 mg/kg肌内注射。
- 咪达唑仑与其他研究药物相比通常显示更多副作用,尤其是呼吸相关副作用。
- 氟哌利多未发现比其他药物死亡率更高,且未观察到对QT间期的影响。
- 纳入的42项研究中无高质量研究,仅6项为中等质量,结论受现有证据质量限制。
适用人群与场景
- 院前环境中发生急性行为障碍(ABD,旧称兴奋性谵妄)的患者。
- 纳入标准:任何考察院前ABD管理的研究,包括随机对照试验、观察性队列研究和病例系列,限英文发表。
处置流程与药物剂量
- 作者认为氯胺酮可能是院前ABD最有效的镇静方法,剂量为5 mg/kg肌内注射。
- 氯胺酮研究中剂量和给药方法差异显著。
- 咪达唑仑与其他研究药物相比通常显示更多副作用,尤其是呼吸相关副作用。
- 氟哌利多未发现比其他药物死亡率更高,且未观察到对QT间期的影响。
研究设计与关键结果
- 系统综述纳入42项研究(来自6091项检索结果),无高质量研究,6项为中等质量。
- 氯胺酮显示最有效的镇静作用,纳入患者中79-98%达到研究定义的充分镇静,但剂量和给药方法差异显著。
- 咪达唑仑与其他研究药物相比通常显示更多副作用。
- 氟哌利多未发现比其他药物死亡率更高,且未观察到对QT间期的影响。
证据类型、等级与局限
- 证据类型:系统性文献综述(PROSPERO CRD42023447238),检索PubMed、Cochrane trials、Cochrane reviews、Embase、Web of Knowledge、Google Scholar和MEDLINE,从建库至2025年2月。
- 方法学质量使用ROBINS-I和GRADE方法评估;纳入42项研究中无高质量研究,6项为中等质量。
- 局限:结论受现有证据质量限制;需要额外研究以确定该人群最有效的给药方式和剂量,以及更好地定义就诊情况和结局指标。
对床旁实践的改变
- 作者认为氯胺酮可能是院前ABD最有效的镇静方法,剂量为5 mg/kg肌内注射。
- 作者指出咪达唑仑与其他镇静药物相比呼吸相关副作用风险较高。
- 作者结论认为需要额外研究以确定该人群最有效的给药方式和剂量,以及更好地定义就诊情况和结局指标。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Acute behavioural disturbance (ABD), formally known as excited delirium, is an under-recognised clinical picture often characterised by abnormal physiology and extreme agitation. The condition is potentially dangerous for both patients and practitioners, particularly in the prehospital setting. Our objective was to systematically review the evidence for management of ABD within the prehospital environment.
METHODS: A systematic literature search (PROSPERO CRD42023447238) of PubMed, Cochrane trials, Cochrane reviews, Embase, Web of Knowledge, Google Scholar and MEDLINE was performed from inception until February 2025. Any study that examined the management of ABD prehospitally was included. Randomised controlled trials, observational cohort studies and case series that were written in English were included. Methodological quality of included studies was interpreted using the ROBINS-I (Risk Of Bias In Non-randomised Studies - of Interventions) and GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach.
RESULTS: From 6091 studies, 42 were included; none were high quality and 6 were moderate quality. Ketamine demonstrated the most effective sedation (range 79-98% of all patients included achieving adequate sedation as defined in the studies), although doses and methods of administration varied significantly. Midazolam generally showed a higher number of side effects than other drugs studied. Droperidol was not found to have a higher mortality than others, and no effect was seen on the QT interval.
CONCLUSIONS: Ketamine was found to be the most studied drug for treatment of ABD in the prehospital setting and is likely the most effective method of sedation at a dose of 5 mg/kg intramuscularly. Midazolam appears to have a higher risk of side effects, particularly respiratory-related, in comparison to other sedative agents. Conclusions are limited by the quality of evidence currently available and additional research is required to establish the most effective mode of administration and dose for this population group, as well as better definition of the presenting condition and outcome measures.
PROSPERO REGISTRATION NUMBER: CRD42023447238.
参考来源
- Smith F, Todd J, Avery P, et al. Prehospital management of acute behavioural disturbance: managing severe agitation in the prehospital setting - a systematic literature review. Emerg Med J. 2026. PMID: 41760406. doi:10.1136/emermed-2025-215690
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。